Nature Communications (Nov 2020)
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
- Sara A. Hurvitz,
- Jennifer L. Caswell-Jin,
- Katherine L. McNamara,
- Jason J. Zoeller,
- Gregory R. Bean,
- Robert Dichmann,
- Alejandra Perez,
- Ravindranath Patel,
- Lee Zehngebot,
- Heather Allen,
- Linda Bosserman,
- Brian DiCarlo,
- April Kennedy,
- Armando Giuliano,
- Carmen Calfa,
- David Molthrop,
- Aruna Mani,
- Hsiao-Wang Chen,
- Judy Dering,
- Brad Adams,
- Eran Kotler,
- Michael F. Press,
- Joan S. Brugge,
- Christina Curtis,
- Dennis J. Slamon
Affiliations
- Sara A. Hurvitz
- David Geffen School of Medicine, University of California Los Angeles
- Jennifer L. Caswell-Jin
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Katherine L. McNamara
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Jason J. Zoeller
- Department of Cell Biology, Harvard Medical School
- Gregory R. Bean
- Department of Pathology, Stanford University School of Medicine
- Robert Dichmann
- Central Coast Medical Oncology
- Alejandra Perez
- Department of Medicine, University of Miami Miller School of Medicine
- Ravindranath Patel
- Comprehensive Blood & Cancer Center
- Lee Zehngebot
- Florida Cancer Specialists & Research Institute
- Heather Allen
- Comprehensive Cancer Centers of Nevada
- Linda Bosserman
- City of Hope Comprehensive Cancer Center
- Brian DiCarlo
- David Geffen School of Medicine, University of California Los Angeles
- April Kennedy
- FCPP Hematology/Oncology
- Armando Giuliano
- Cedars-Sinai Medical Center
- Carmen Calfa
- Department of Medicine, University of Miami Miller School of Medicine
- David Molthrop
- Florida Cancer Specialists & Research Institute
- Aruna Mani
- Genentech
- Hsiao-Wang Chen
- David Geffen School of Medicine, University of California Los Angeles
- Judy Dering
- David Geffen School of Medicine, University of California Los Angeles
- Brad Adams
- David Geffen School of Medicine, University of California Los Angeles
- Eran Kotler
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Michael F. Press
- Department of Pathology, Keck School of Medicine, University of Southern California
- Joan S. Brugge
- Department of Cell Biology, Harvard Medical School
- Christina Curtis
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Dennis J. Slamon
- David Geffen School of Medicine, University of California Los Angeles
- DOI
- https://doi.org/10.1038/s41467-020-19494-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the pathological and molecular responses associated with trastuzumab and/or lapatinib in combination with chemotherapy in HER2+ breast cancer patients.
